Quick answer: Sculptra and Radiesse are FDA-approved injectable implants made from different materials and approved for different uses. Sculptra contains poly-L-lactic acid, or PLLA. Radiesse contains calcium hydroxylapatite, or CaHA. They are not interchangeable, and the right choice depends on anatomy, treatment area, desired effect, product labeling, and individual risk.
| Question | Sculptra | Hyperdilute Radiesse |
|---|---|---|
| Primary material | Poly-L-lactic acid, or PLLA | Calcium hydroxylapatite, or CaHA, diluted with sterile saline |
| How change develops | Gradual change after a staged tissue response | A less volumizing preparation designed for skin-quality goals in the labeled décolleté use |
| FDA context | Approved for specified facial wrinkles and cheek fine lines in immune-competent people | FDA approved 1:2 diluted Radiesse for décolleté wrinkles in adults on March 31, 2026 |
| Other treatment areas | Some proposed facial areas may be outside current labeling | Diluted use outside the décolleté may be off-label; standard Radiesse formulations have separate indications |
| Dissolved by hyaluronidase? | No | No |
| General regional price range | $800 to $1,200 per vial | $800 to $1,400 per syringe |
FDA approvals depend on the exact product, formulation, dilution, injection plane, and treatment area. A comparison table cannot replace review of the current patient labeling and a discussion of on-label and off-label use.
Maura Reinblatt, MD, is board certified in plastic surgery and general surgery. She completed general-surgery residency training at Massachusetts General Hospital and Harvard Medical School and plastic-surgery residency training at UCLA Medical Center. Her White Plains practice describes a conservative approach to facial injectables, with the goal of subtle, natural-looking change rather than an overfilled appearance.
For selected facial injection cases, ultrasound can help a trained clinician visualize anatomy beneath the skin. Ultrasound does not eliminate the possibility of vascular occlusion or another complication, and it should not replace product knowledge, anatomy, injection training, informed consent, or an emergency plan. Related page: Learn about ultrasound guidance for facial injections.
The term collagen stimulator is commonly used for injectables whose aesthetic effect can continue to develop after treatment. Sculptra is an injectable implant containing PLLA microparticles. Radiesse is an injectable implant containing CaHA microspheres in a gel carrier. Because their materials and labeling differ, a recommendation should identify the exact product and intended treatment area rather than treating them as one category.
These products are also different from hyaluronic acid fillers. Hyaluronic acid fillers can often be reduced with hyaluronidase. Sculptra and Radiesse are not hyaluronic acid products and are not dissolved by hyaluronidase.
Sculptra is an injectable PLLA implant. FDA-approved aesthetic labeling includes correction of shallow to deep nasolabial-fold contour deficiencies and other facial wrinkles in which the labeled injection technique is appropriate. In 2023, the FDA expanded the indication to include fine lines and wrinkles in the cheek region in immune-competent people.
Sculptra is reconstituted before injection, and the aesthetic effect develops gradually. The number of sessions and amount used should be individualized. Treatment at an area or frequency outside current labeling may be off-label and should be explained as such.
Radiesse contains CaHA microspheres. Standard Radiesse and Radiesse (+) formulations have FDA-approved indications that include certain moderate to severe facial wrinkles and folds, hand volume loss, and jawline contour loss, depending on the exact formulation.
On March 31, 2026, the FDA approved Radiesse diluted 1:2 with 0.9% sterile saline for subdermal correction of décolleté wrinkles in adult patients. Hyperdiluted Radiesse uses a different ratio or in another area, such as parts of the face or neck, may be off-label. Off-label use can be medically appropriate, but it should be disclosed and discussed before treatment.
Sculptra may be considered when the goal and facial area fit its labeled uses and a gradual treatment plan. Hyperdilute Radiesse may be considered for the FDA-approved décolleté indication or, after informed consent, for a clinician-selected off-label use. The decision depends on anatomy, skin quality, desired degree of volume, prior filler, medical history, product reversibility, and comfort with a staged result.
A responsible consultation should also consider whether a hyaluronic acid filler, neuromodulator, laser or energy-based procedure, skin treatment, surgery, or no treatment is a better fit.
Injectable treatment may need to be delayed or avoided when there is an active infection or inflammation at the treatment site, a relevant severe allergy, a bleeding disorder, or another product-specific contraindication. Sculptra should not be used in people with a known history of or susceptibility to keloid formation or hypertrophic scarring. Safety during pregnancy or breastfeeding may not be established for a proposed treatment.
This is not a complete screening list. Review the current patient labeling and tell Dr. Reinblatt about medications, allergies, prior filler or surgery, dental work, infections, vaccinations, immune conditions, and previous injection reactions.
Treatment begins with an examination and a discussion of goals, product choice, exact treatment area, expected timing, alternatives, and risks. The office should identify the specific product and, for Radiesse, whether it will be used in a standard or diluted form. The skin is cleansed, comfort measures may be used, and the product is placed with a needle or cannula according to the treatment plan.
Some plans involve more than one session. The number of sessions, spacing, amount, and aftercare vary by product, area, and individual response. A fixed package should not be presented as medically necessary for every patient.
Common dermal-filler effects include bruising, redness, swelling, pain, tenderness, itching, and rash. Other risks include infection, delayed inflammation, nodules or granulomas, asymmetry, migration, open or draining wounds, allergic reaction, and tissue damage. Some reactions can appear weeks, months, or years after injection.
The most concerning filler risk is unintended injection into a blood vessel. Although uncommon, vascular occlusion can cause skin necrosis, vision abnormalities including blindness, or stroke. Seek immediate medical attention for unusual or severe pain, vision changes, a white, gray, or blue appearance of skin near the injection site, or signs of stroke.
Sculptra and hyperdilute Radiesse are chosen when gradual change is acceptable. Exact timing and duration vary with the product, indication, treatment area, amount, technique, anatomy, and individual response. Published maximum-duration claims should not be presented as a guarantee for an individual patient.
Published White Plains, Westchester, and nearby New York pricing suggests a general price range of about $800 to $1,200 per Sculptra vial and about $800 to $1,400 per Radiesse syringe. Total cost can extend into several thousand dollars because the number of vials or syringes and the number of sessions are individualized. Treatment area, dilution, provider, and product plan can also affect the total. Dr. Reinblatt's office will confirm the current fee after consultation.
Yes, for one specific use. On March 31, 2026, the FDA approved Radiesse diluted 1:2 with 0.9% sterile saline for subdermal correction of décolleté wrinkles in adults. Other dilution ratios or treatment areas may be off-label.
No. Sculptra contains PLLA, and Radiesse contains CaHA. Hyaluronic acid fillers use a different material and can often be reduced with hyaluronidase. Sculptra and Radiesse are not dissolved by hyaluronidase.
The number of treatments is individualized. It depends on the product, labeled or off-label use, treatment area, goals, amount placed, response, and safety considerations.
A combined plan may be considered, but each product addresses a different treatment goal and adds its own risks, timing, and aftercare. The sequence should be planned after an examination rather than assumed in advance.
Sculptra and Radiesse cannot be dissolved with hyaluronidase. Managing an unwanted effect or complication may require observation, medication, injections, drainage, excision, surgery, or other care depending on the problem.
Injection can cause discomfort. Product formulation, treatment area, needle or cannula technique, ice, topical anesthetic, or lidocaine may affect the experience. Comfort measures do not remove the need to discuss risks.
To compare Sculptra, standard or hyperdilute Radiesse, hyaluronic acid fillers, and other options, schedule a consultation at Dr. Maura Reinblatt's office at 12 Greenridge Avenue, Suite 401, White Plains, NY 10605. The recommendation should identify the exact product, treatment area, regulatory status, expected timing, alternatives, risks, and follow-up plan.
Sculptra and hyperdilute Radiesse offer a gradual, non-surgical way to address volume loss and skin quality. Contact Dr. Reinblatt's office today to schedule a consultation.
Schedule12 Greenridge Ave #401, White Plains, NY 10605
(646) 905-0087